Last reviewed · How we verify

Tiragolumab and Atezolizumab IV FDC

Hoffmann-La Roche · Phase 2 active Small molecule

Tiragolumab and Atezolizumab IV FDC is a Small molecule drug developed by Hoffmann-La Roche. It is currently in Phase 2 development.

At a glance

Generic nameTiragolumab and Atezolizumab IV FDC
SponsorHoffmann-La Roche
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tiragolumab and Atezolizumab IV FDC

What is Tiragolumab and Atezolizumab IV FDC?

Tiragolumab and Atezolizumab IV FDC is a Small molecule drug developed by Hoffmann-La Roche.

Who makes Tiragolumab and Atezolizumab IV FDC?

Tiragolumab and Atezolizumab IV FDC is developed by Hoffmann-La Roche (see full Hoffmann-La Roche pipeline at /company/roche).

What development phase is Tiragolumab and Atezolizumab IV FDC in?

Tiragolumab and Atezolizumab IV FDC is in Phase 2.

Related